App-Quantinova.ai

UK CLL forum 5 years update on 315 relapsed refractory CLL patients treated with ibrutinib in 66 UK and Ireland centres

U. CLL Forum - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Idelalisib

Escalated BEACOPDac as first line therapy in 100 Hodgkin lymphoma patients reduces red cell transfusion requirements and may shorten time to menstrual period recovery whilst maintaining efficacy compared to escalated BEACOPP

A. Santarsieri - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

N/A

Brentuximab vedotin plus bendamustine in relapsed and refractory classical Hodgkin lymphoma in children, adolescents and young adults: a single centre experience

A. McMillan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

The addition of Molecular High Grade classification to CNS International Prognostication Index and Cell of Origin may improve prediction of CNS relapse in Diffuse Large B Cell Lymphoma

R. Kemp - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Adoption of rapid obinutuzumab infusions: real world experience

J. Cunningham - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4‐year update of the ECHELON‐1 study

J. Radford - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

Structural and functional variability of the tumour B‐cell receptor indicates a role for environmental influences on the behaviour of mantle cell lymphoma

D. Dutton - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

An international multicentre study of consecutively diagnosed patients with ALCL: outcomes following first‐line therapy in routine clinical practice

N. Martinez-Calle - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real world analysis of outcomes in 185 Patients

R. McCulloch - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

Ibrutinib

Finding the five percent: predicting adult T‐cell leukaemia/lymphoma (ATLL) in human T‐cell leukaemia virus‐1 (HTLV‐1) carriers using a novel flow cytometric method

S. Wolf - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adult T-Cell Leukemia

N/A

Investigating the clinical utility of a next generation sequencing B‐cell clonality assay. case study: identification ighv4‐34 rearrangement and assess its prognostic value in hairy cell leukaemia

K. Quevedo - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hairy cell leukemia

N/A

Cost‐effectiveness of a 24‐month fixed duration of venetoclax in combination with rituximab in relapse/refractory chronic lymphocytic leukaemia

N. Coll Bastus - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Cyclophosphamide

Serial troponin measurement during anthracycline‐containing chemotherapy may predict early cardiotoxicity that is amenable to primary prevention with ACE inhibitors

I. Cakmak - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Diffuse large B-cell lymphoma

Ramipril

Successful employment of spatial imaging mass cytometry in follicular lymphoma confirms a central role of follicular helper T‐cells in disease pathogenesis

E. Phillips - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

N/A

Minimal residual disease and the prediction of survival outcomes in chronic lymphocytic leukaemia: a pooled analysis of observational and clinical trial data

E. Ngonga Kemadjou - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

Incidence of BTK mutations in chronic lymphocytic leukaemia treated with BTK inhibitors in a single UK institution

E. Santambrogio - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

ACP-196

Lymph node core biopsy: outcomes from 554 consecutive biopsies and prospective patient experience survey demonstrate a safe, rapid, reliable diagnostic method for lymphoma

A. Dervin - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

Exploiting VDJ recombination of T cells to dissect the anti‐cancer immune interactions in T cell lymphoma

D. Murray - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mycosis fungoides

N/A

An immunocompetent, spontaneous mouse model of DLBCL for studying the response to R‐CHOP and identifying new treatment targets

B. Maybury - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Cyclophosphamide

Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON‐2 trial

T. Illidge - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adult T-Cell Leukemia

Adcetris

Filters

45280 Abstracts